Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study.

Douglass, Edwin C.; Reynolds, Marleta; Finegold, Milton J.; Cantor, Alan; Glicksman, Arvin S.

doi:10.1200/jco.1993.11.1.96

Cited by 168 publications

(114 citation statements)

References 0 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…These authors refined the criteria for PFH to require Յ 2 mitoses per 10 high-power (ϫ400 magnification) fields and stipulated that the entire tumor exhibit fetal histology. Douglass et al 10 reported on four patients with stage I PFH tumors who survived with resection alone in the Pediatric Oncology Group Studies 8696 and 8697.…”

Section: Discussionmentioning

confidence: 99%

“…Subsequent clinical trials have shown that cisplatin-based chemotherapy improves survival by increasing tumor resectability, treating metastatic disease, and reducing the incidence of local and distant relapse. [8][9][10][11][12] In the prechemotherapy era, Kasai and Watanabe 13 reported that among children with resectable tumors, there was a higher rate of survival for children with fetal histology than for those with anaplastic or poorly differentiated small-cell histology. Weinberg and Finegold 14 similarly reported long-term survival for six children who had completely resected tumors of pure fetal histology (PFH), whereas only two of 10 patients with other histologic cell types survived.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Complete Surgical Resection Is Curative for Children With Hepatoblastoma With Pure Fetal Histology: A Report From the Children's Oncology Group

Malogolowkin

Katzenstein

Meyers

et al. 2011

JCO

165

View full text Add to dashboard Cite

Purpose Children with pure fetal histology (PFH) hepatoblastoma treated with complete surgical resection and minimal adjuvant therapy have been shown to have excellent outcomes when compared with other patients with hepatoblastoma. We prospectively studied the safety and efficacy of reducing therapy in all children with stage I PFH enrolled onto two consecutive studies. Patients and Methods From August 1989 to December 1992, 9 children with stage I PFH were treated on the Intergroup Hepatoblastoma study INT-0098 and were nonrandomly assigned to receive chemotherapy after surgical resection with single-agent bolus doxorubicin for 3 consecutive days. From March 1999 to November 2006, 16 children with stage I PFH enrolled onto Children's Oncology Group Study P9645 were treated with observation after resection. Central confirmation of the histologic diagnosis by a study group pathologist was mandated. The extent of liver disease was assigned retrospectively according to the pretreatment extent of disease (PRETEXT) system and is designated “retro-PRETEXT” to clarify the retrospective group assignment. Results Five-year event-free and overall survival for the 9 patients treated on INT-0098 were 100%. All 16 patients enrolled onto the P9645 study were alive and free of disease at the time of last contact, with a median follow-up of 4.9 years. Retro-PRETEXT for the 21 patients with available data revealed seven patients with stage I disease, 10 patients with stage II disease, and four patients with stage III disease. Conclusion Children with completely resected PFH hepatoblastoma can achieve long-term survival without additional chemotherapy. When feasible, surgical resection of hepatoblastoma at diagnosis, without chemotherapy, can identify children for whom no additional therapy is necessary.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Complete Surgical Resection Is Curative for Children With Hepatoblastoma With Pure Fetal Histology: A Report From the Children's Oncology Group

Malogolowkin

Katzenstein

Meyers

et al. 2011

JCO

165

View full text Add to dashboard Cite

show abstract

“…Small-cell-undifferentiated hepatoblastoma belongs to the clinically important group of hepatoblastomas that show low or normal serum AFP levels, 23,24 and it has been shown to be associated with an aggressive biology 3,25,26 and worse survival. 4,5,24 A recent report from the COG has shown that small-cell-undifferentiated histology is a prognostic factor for an increased risk of death.…”

Section: Cholangioblastic Hepatoblastomamentioning

confidence: 99%

Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium

Alaggio²,

et al. 2014

View full text Add to dashboard Cite

Liver tumors are rare in children, and their diagnoses may be challenging particularly because of the lack of a current consensus classification system. Systematic central histopathological review of these tumors performed as part of the pediatric collaborative therapeutic protocols has allowed the identification of histologic subtypes with distinct clinical associations. As a result, histopathology has been incorporated within the Children's Oncology Group (COG) protocols, and only in the United States, as a risk-stratification parameter and for patient management. Therefore, the COG Liver Tumor Committee sponsored an International Pathology Symposium in March 2011 to discuss the histopathology and classification of pediatric liver tumors, and hepatoblastoma in particular, and work towards an International Pediatric Liver Tumors Consensus Classification that would be required for international collaborative projects. Twenty-two pathologists and experts in pediatric liver tumors, including those serving as central reviewers for the COG, European Socié té Internationale d'Oncologie Pé diatrique, Gesellschaft fü r Pä diatrische Onkologie und Hä matologie, and Japanese Study Group for Pediatric Liver Tumors protocols, as well as pediatric oncologists and surgeons specialized in this field, reviewed more than 50 pediatric liver tumor cases and discussed classic and newly reported entities, as well as criteria for their classification. This symposium represented the first collaborative step to develop a classification that may lead to a common treatment-stratification system incorporating tumor histopathology. A standardized, clinically meaningful classification will also be necessary to allow the integration of new biological parameters and to move towards clinical algorithms based on patient characteristics and tumor genetics, which should improve future patient management and outcome.

show abstract

“…Preoperative chemotherapy has improved the outcome for patients by shrinking tumors, thereby increasing the proportion of resectable lesions. Several chemotherapeutic combinations have been shown to be effective, cisplatin being the core of most regimens [5,7,8]. However, a challenge occurs when treating neonates with chemotherapeutic agents that require renal or hepatic metabolism or excretion; neither of these organs is fully developed even in a full-term infant.…”

mentioning

confidence: 98%

Congenital hepatoblastoma and schizencephaly in an infant with Beckwith-Wiedemann syndrome

Worth

Slopis²,

Herzog

1999

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study.

Abstract: Relatively brief exposure to chemotherapy with CDDP/VCR/FU provided excellent disease control to patients with grossly resected tumors. In patients with initially unresectable disease, this therapy provides a response rate and DFS rate comparable to regimens that contain doxorubicin (DOX).

Cited by 168 publications

References 0 publications

Complete Surgical Resection Is Curative for Children With Hepatoblastoma With Pure Fetal Histology: A Report From the Children's Oncology Group

Complete Surgical Resection Is Curative for Children With Hepatoblastoma With Pure Fetal Histology: A Report From the Children's Oncology Group

Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium

Congenital hepatoblastoma and schizencephaly in an infant with Beckwith-Wiedemann syndrome

Contact Info

Product

Resources

About